NeutralLOW severityHealthcare & Pharma8d ago

Charles River to acquire Frontage's bioanalysis and DMPK operations for $470M cash

Charles River to acquire Frontage's bioanalysis and DMPK operations for $470M cash — $CRL one-month chart
$CRL daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOK’s read

Charles River last traded at $350.24, up 3.77%, near the top of its 52-week range. The stock is at 87% of its range, with a high of $379.63, and recent coverage has been neutral, concentrated in the last week. The Health Care sector is calm today.

Written by Wook AI Nov 9, 9:52 AM ET from this page’s own figures at that time — not from the article — with every number checked against them. Not investment advice.

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about CRL. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · charles riverEvent risk Low

Nothing reported about charles river across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 68% a year
Now $334.32Week $302.18–$366.46 (±9.6%)Month $268.46–$400.18 (±19.7%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: $CRL's deal hinges on more than just the price — how it's paid, who's funding it, and if regulators greenlight the move could shape its future more than the headline suggests.
  • How the stock is trading: $CRL -0.36% in the latest session.
  • Timing: It came out pre-market, so the next session was the first that could react.
Amount$470 million

Where the stock stands

Charles River Laboratories Inte ($CRL) slipped 0.36% to $334.32 in the latest session. Over the past month it is up 11.4%. It now sits 12% under the 52-week high of $379.63 and 129% above the year's low of $146.20. It has been a volatile year: the high was 2.6 times the low, so moves this size are not unusual for it.

What the filings say

In its latest report (10-Q, filed Nov 4, 2026), $CRL earned $333.1M over the quarter to Sep 26, 2026 on revenue of $982.7M (-2.1% QoQ). Operations brought in $474.9M of cash over the nine months to Sep 26, 2026; after capital spending, free cash flow was $341.1M. Total liabilities were $4.18B against $200.4M of cash on Sep 26, 2026. The company filed an 8-K — the form for material events — on Nov 9, the same day as this story; it is $CRL's own account and the first thing to read. Figures are as filed with the SEC; the $CRL page has the full statements.

How much coverage it is getting

Wook has filed 2 stories on Charles River Laboratories Inte in the last 30 days, 0 of them this week. None came this week, so coverage has gone quiet. Going by their wording, 0 read bullish, 2 neutral and 0 bearish. This one reads neutral too, in line with most of them. 2 came from Seeking Alpha and the rest from other outlets, so more than one newsroom is on it.

The bigger picture

In healthcare, timing is everything — a single trial result or FDA decision can shift a drugmaker's fate, while broader policy shifts ripple across the entire industry. Wook's supply-chain scanner shows no unusual stress in Health Care today.

What to watch next

The $CRL page has all the charts, filings, and models to back up every number. Comparing coverage from different outlets is key to spotting confirmation or repetition. Wook AI can pull live data and run the numbers on request — like how far $CRL is from its peak or how this week's coverage stacks up.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Seeking Alpha published this on November 9, 2026. $CRL has moved -2.25% ($342.00 to $334.32). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Seeking Alpha. Wook of Wall Street is an independent research tool and is not affiliated with Seeking Alpha. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy